Objective To investigate the clinical effect of flupentixol and melitracen tablets combined with Shugan Jieyu capsule on the treatment of patients with refractory gastroesophageal reflux disease (GERD).
Methods A total of 90 patients with refractory GERD were randomly divide into control group and research group, with 45 cases in each group. The control group was treated with lansoprazole enteric-coated capsules plus mosapride citrate, while the research group was treated with flupentixol and melitracen tablets (Delixin) and Shugan Jieyu Capsules on the basis of the control group. The scores of symptoms of GERD, Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were compared before treatment and 6, 12 weeks after treatment between two groups, and the clinical efficacy and safety was evaluated between two groups.
Results There was 1 case of dropout in the research group. The scores of Reflux Disease Questionnaire (RDQ), HAMD and HAMA in both groups at 6 and 12 weeks of treatment were significantly lower than those before treatment (P < 0.05), and these indexes of the research group at 6 and 12 weeks of treatment were significantly lower than those of the control group (P < 0.05). The total effective rate was 95.45% in the researchgroup, which was significantly higher than 80.00% in the control group (P < 0.05). There were only a few mild discomfort symptoms in the two groups during the treatment period.
Conclusion On the basis of routine PPI optimal treatment, flupentixol andmelitracen tablets combined with Shugan Jieyu Capsule can effectively relieve the clinical symptoms of refractory GERD and improve the mental state.
DownLoad: